We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide
Drugmaker’s chief executive Pascal Soriot had talks last year about a role with US group Biogen
Committees cite inappropriate collaboration between FDA and drugmaker
Dementia drug development, diagnostics and delivery still require much more investment
Shares fall 11% following two patient deaths in trials of lecanemab
The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down
Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease
Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts
Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis
Biogen chief to step down after the company’s Alzheimer’s drug flops
US biotech to dismantle sales infrastructure for treatment as it begins search for successor
FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say
Insurers’ reluctance to pay for Aduhelm treatment forces biotech to lower costs as EMA highlights safety concerns
Vote by European Medicines Agency panel deals setback to controversial $56,000-a-year treatment
Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m
Pharma group blames ‘misinformation’ for overshadowing approval of therapy
US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment
Hypothesis that brain plaques cause disease viewed with scepticism by some scientists
Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’
US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high
FDA decision on aducanumab must bring benefits beyond Biogen’s bottom line
Lofty prices reward risky, expensive research. But aducanumab’s pricing will raise eyebrows
Campaigners hit out at high price for controversial treatment that has divided scientists
FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy
Biogen’s aducanumab would be first new treatment in years for disease if approved by FDA
UK Edition
